An experimental targeted drug could provide a fresh chance for people with recurring head and neck cancer that has grown resistant to other treatments, a new clinical trial says. Ficlatuzumab used in combination with the already approved targeted drug cetuximab (Erbitux) significantly improved progression-free survival in relapsed head and neck cancer patients, according to results from a phase II trial. The results are particularly encouraging because the ficlatuzumab/cetuximab combo only worked in patients whose cancers aren’t driven by human papillomavirus (HPV) infection, said lead researcher Dr. Julie Bauman, director of the GW Cancer Center at George Washington University in Washington, D.C. “People with HPV-positive virally driven cancer have a better prognosis. They usually respond better to just about any therapy that’s put in front of them,” Bauman said. Patients with “the worst of the worst prognosis, with HPV-negative disease, was the group that appeared to disproportionately benefit, which was unexpected and quite gratifying,” Bauman said. HPV-negative head and neck cancers are typically driven by alcohol or tobacco use or exposure to occupational pollutants. The combo therapy had a 38% response rate in HPV-negative head and neck cancer patients. In those patients, tumors shrank by at least 30%. “This was a very sick patient population, because these were patients who had had their cancer come back after initial treatment, and they were all resistant to chemotherapy,… read on > read on >







